4D Molecular Therapeutics (FDMT)

We received a question on the chart for 4D Molecular Therapeutics (FDMT), a small cap biotech name.

FDMT: Holds support (10.03-9.63) and reasserts uptrend for the 12- and 15-handles

A breakout above 7.59 confirmed a December 2024-September 2025 bottoming pattern for FDMT that favors upside to 12.43-12.85 (38.2% of the July 2024-April 2025 decline). FDMT approached this upside target in late October prior to a pullback into early November.

This pullback defended key chart support and the rising 40-day moving average (DMA) in the 10.03 to 9.62 area to reassert the bullish setup with potential to 12.43-12.85 and then toward 15.23-15.58 (key 50% and 38.2% retracement levels).

Closes above the 13- and 26-DMAs from 11.13 to 10.64 would keep the immediate bias to the upside. The 10.03-9.62 range remains key support from a risk management perspective.

FDMT is scheduled to report earnings on Friday, November 14th before the market open.

Chart 1: 4D Molecular Therapeutics (FDMT)